The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 17 September 2018 or when the announcement is released to the market.
Read the trading halt announcement.
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal